<DOC>
	<DOCNO>NCT02470286</DOCNO>
	<brief_summary>This study block-randomized , double-blind , placebo-controlled , single/multiple-dose , dose-escalation , Phase I clinical study investigate pharmacokinetics safety/tolerability SA001 healthy male volunteer .</brief_summary>
	<brief_title>Clinical Study Investigate Pharmacokinetics Safety/Tolerability SA001 Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male Korean 1945 year Body weight:5590kg , BMI:18.027.0 Present condition history clinically significant disease Clinical evidence history GI disease history GI surgery History hypersensitivity , include drug allergy AST ( SGOT ) ALT ( SGPT ) &gt; 1.5 time upper normal limit eGFR &lt; 90mL/min/1.73m2 Systolic blood pressure : &lt; 100 mmHg &gt; 160 mmHg Diastolic blood pressure : &lt; 60 mmHg &gt; 100 mmHg QTcF &gt; 430msec ( male ) PR interval &gt; 200msec &lt; 110msec Evidence 2nd 3rddegree atrioventricular ( AV ) block Pathologic Q wave ( define Qwave &gt; 40msec depth &gt; 0.5mV ) Evidence ventricular preexicitation , leave bundle branch block ( LBBB ) , right bundle branch block ( RBBB , Incomplete RBBB ) Family history Long QT syndrome , sudden death risk factor Torsade de point include heart failure , hypopotassemia , arrhythmia Drug abuse within 60 day , positive reaction Drug test Urine Taken ETC herbal supplement within 14 day OTC vitamin supplement within 7 day Participation administration IP another clinical trial within 90 day Donation whole blood within 60 day , blood component receipt blood transfusion within 30 day Consumption 21 unit alcohol/week inability abstain drink study period Smoking within 90 day Taking caffeine grapefruitcontaining product within 3 day Plan pregnant , use appropriate method contraception</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>